secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001140361-25-038031
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst to acquire Astria Therapeutics for 0.59 shares + $8.55 cash per share; Q3 ORLADEYO strong
--------------------------------------------------------------------------------

- Merger: each Astria share → 0.59 BCRX shares + $8.55 cash; expected close Q1 2026.
- Blackstone provides $550M senior secured credit facility ($350M term loan + $50M committed delayed draw + $150M uncommitted) to fund deal.
- Q3 2025: ORLADEYO demand strong with no impact from new competition (no specific figures given).
- Astria CEO Jill Milne appointed to BioCryst board effective at merger close; receives $500K equity grant.
- BioCryst paid off and terminated April 2023 loan agreement with BioPharma Credit PLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000114036125038031/0001140361-25-038031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000114036125038031/ef20057029_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-038031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer